A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Nitin B. Charbe; Francisco Castillo; Murtaza M. Tambuwala; Parteek Prasher; Dinesh Kumar Chellappan; Aurora Carreño; Saurabh Satija; Sachin Kumar Singh; Monica Gulati; Kamal Dua; José Vicente González-Aramundiz; Flavia C. Zacconi

doi:10.1016/j.blre.2022.100927

A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Nitin B. Charbe
, Francisco Castillo
, Murtaza M. Tambuwala
, Parteek Prasher
, Dinesh Kumar Chellappan
, Aurora Carreño
, Saurabh Satija
, Sachin Kumar Singh
, Monica Gulati
, Kamal Dua
, José Vicente González-Aramundiz
, Flavia C. Zacconi

Pontificia Universidad Católica de Chile
Texas A&M University
Ulster University
Guru Nanak Dev University
University of Petroleum and Energy Studies
International Medical University
Universidad Industrial de Santander
University of Technology Sydney
Lovely Professional University

Research output: Contribution to journal › Review article › peer-review

54 Scopus citations

Abstract

Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

Original language	English
Article number	100927
Journal	Blood Reviews
Volume	54
DOIs	https://doi.org/10.1016/j.blre.2022.100927
State	Published - Jul 2022
Externally published	Yes

Keywords

Blood transfusion
Haemoglobin-based oxygen carriers (HBOCs)
Nitric oxide scavenging
Perfluorocarbons (PFCs)
Recombinant haemoglobin
Vasoconstriction

Access to Document

10.1016/j.blre.2022.100927

Cite this

Charbe, N. B., Castillo, F., Tambuwala, M. M., Prasher, P., Chellappan, D. K., Carreño, A., Satija, S., Singh, S. K., Gulati, M., Dua, K., González-Aramundiz, J. V., & Zacconi, F. C. (2022). A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers. Blood Reviews, 54, Article 100927. https://doi.org/10.1016/j.blre.2022.100927

@article{1f677c5e634d4f62932cdec3d4d08fae,

title = "A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers",

abstract = "Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.",

keywords = "Blood transfusion, Haemoglobin-based oxygen carriers (HBOCs), Nitric oxide scavenging, Perfluorocarbons (PFCs), Recombinant haemoglobin, Vasoconstriction",

author = "Charbe, \{Nitin B.\} and Francisco Castillo and Tambuwala, \{Murtaza M.\} and Parteek Prasher and Chellappan, \{Dinesh Kumar\} and Aurora Carre{\~n}o and Saurabh Satija and Singh, \{Sachin Kumar\} and Monica Gulati and Kamal Dua and Gonz{\'a}lez-Aramundiz, \{Jos{\'e} Vicente\} and Zacconi, \{Flavia C.\}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.blre.2022.100927",

language = "English",

volume = "54",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

AU - Charbe, Nitin B.

AU - Castillo, Francisco

AU - Tambuwala, Murtaza M.

AU - Prasher, Parteek

AU - Chellappan, Dinesh Kumar

AU - Carreño, Aurora

AU - Satija, Saurabh

AU - Singh, Sachin Kumar

AU - Gulati, Monica

AU - Dua, Kamal

AU - González-Aramundiz, José Vicente

AU - Zacconi, Flavia C.

PY - 2022/7

Y1 - 2022/7

N2 - Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

AB - Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

KW - Blood transfusion

KW - Haemoglobin-based oxygen carriers (HBOCs)

KW - Nitric oxide scavenging

KW - Perfluorocarbons (PFCs)

KW - Recombinant haemoglobin

KW - Vasoconstriction

UR - https://www.scopus.com/pages/publications/85123713657

U2 - 10.1016/j.blre.2022.100927

DO - 10.1016/j.blre.2022.100927

M3 - Review article

C2 - 35094845

AN - SCOPUS:85123713657

SN - 0268-960X

VL - 54

JO - Blood Reviews

JF - Blood Reviews

M1 - 100927

ER -

A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this